FDA approves test to predict precursor to heart disease, other chronic illnesses

SAN DIEGO The Food and Drug Administration has given approval to AntiCancer unit A/C Diagnostics to market its A/C Portable Enzymatic Homocysteine Assay on it’s A/C Diagnostic Reader, the company said Friday.

Combined with the small fluorescence reader, the assay uses a genetically engineered enzyme to detect hyperhomocysteinimia, a risk factor for heart disease and other diseases. The company said the test was precise and could be carried out in a small lab, a doctor’s office or a pharmacy because it required small amounts of blood.